Poprotskiy Alexey / Shutterstock.com
The US Food and Drug Administration (FDA) approved Sandoz’s cancer product Zarxio (filgrastim-sndz) on Friday (March 6)—the first biosimilar to be rubber stamped in the US.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Zarxio, biosimilar, FDA, Sandoz, BPCIA, filgrastim, Zarzio